News
2d
Zacks.com on MSNAstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...
3d
Zacks.com on MSNSMMT Stock Gains on Rumored Licensing Talks With AstraZenecaSummit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
AstraZeneca's Calquence hits the mark in the AMPLIFY combination trial in CLL, which could unlock a blockbuster opportunity for the BTK inhibitor.
AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, which the company has said could be a blockbuster new indication for the drug. The European Commission has cleared ...
Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.
3d
MedPage Today on MSNTime-Limited or Indefinite Therapy in CLLTime-limited (or fixed-duration) therapy offers a treatment-free interval, potentially leading to improved quality of life ...
Review the current AstraZeneca PLC ADR (AZN:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if AZN is the best investment for you.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results